6.1594
Xeris Biopharma Holdings Inc Aktie (XERS) Neueste Nachrichten
XERS Technical Analysis | Trend, Signals & Chart Patterns | XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) - ChartMill
What Xeris Biopharma Holdings (XERS)'s Profit Return and Higher 2026 Guidance Means For Shareholders - Sahm
Xeris Biopharma Holdings, Inc. (XERS) Stock Price, News, Quote & History - Yahoo Finance
Xeris Biopharma Quality Draws Market Attention Through Growth Signals - Kalkine Media
Xeris Biopharma Holdings, Inc. (XERS) Latest Stock News & Headlines - Yahoo Finance
Shareholders Will Be Pleased With The Quality of Xeris Biopharma Holdings' (NASDAQ:XERS) Earnings - simplywall.st
Vanguard Group Inc. Buys 1,358,760 Shares of Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
TradingKey - TradingKey
Xeris Biopharma (XERS) Stock Price, News & Analysis $XERS - MarketBeat
Xeris Biopharma Q3 EPS Forecast Decreased by HC Wainwright - MarketBeat
A Look At Xeris Biopharma Holdings (XERS) Valuation After Its Profit Turnaround And Guidance Hike - Sahm
Xeris forecasts $380M-$390M 2026 revenue as Recorlev commercial expansion ramps in H2 - MSN
Results: Xeris Biopharma Holdings, Inc. Confounded Analyst Expectations With A Surprise Profit - Yahoo Finance
Number of shareholders of Xeris Biopharma Holdings, Inc. – DUS:2B30 - TradingView
Xeris Biopharma Q1 Earnings Call Highlights - MarketBeat
Q1 2026 Xeris Biopharma Holdings Inc Earnings Call Transcript - GuruFocus
Xeris Biopharma Holdings, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Xeris Biopharma Holdings (XERS) Is Up 8.2% After Swing to Q1 ProfitabilityWhat's Changed - Yahoo Finance
Xeris Biopharma Reports First Quarter 2026 Financial Results - BioSpace
Xeris (XERS) Q1 2026 Earnings Call Transcript - The Globe and Mail
Rekorlev-driven revenue lifts Xeris Biopharma (XERS) to Q1 2026 profitability - Stock Titan
Earnings call transcript: Xeris Biopharma Q1 2026 reports solid growth By Investing.com - Investing.com South Africa
Xeris Biopharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
XERS: Q1 revenue jumped 43% year-over-year, prompting a raised full-year outlook to $380–$390 million - TradingView
Xeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Xeris Biopharma (NASDAQ:XERS) Achieves First Profit, Beats Q1 Estimates with 95% Recorlev Surge - ChartMill
Earnings Flash (XERS) Xeris Biopharma Holdings Posts Q1 EPS $0.01, vs. FactSet Est of $0.01 Loss per Share - marketscreener.com
Xeris Biopharma: Q1 Earnings Snapshot - Barchart.com
Xeris Biopharma (XERS) surges with 38% Q1 revenue growth and profit - Stock Titan
Xeris Pharmaceuticals Q1 2026 earnings preview - MSN
Insider Sell Alert: Beth Hecht Sells 16,667 Shares of Xeris Biop - GuruFocus
Insider Sell Alert: Beth Hecht Sells 16,667 Shares of Xeris Biopharma Holdings Inc (XERS) - GuruFocus
Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock - MarketBeat
Xeris Biopharma’s chief legal officer sells $103,805 in stock By Investing.com - Investing.com Canada
Xeris Biopharma’s chief legal officer sells $103,805 in stock - Investing.com
Xeris Biopharma (XERS) officer sells 16,667 shares under 10b5-1 plan - Stock Titan
Xeris Biopharma (XERS) to Release Earnings on Thursday - MarketBeat
Xeris Biopharma Reports Third Quarter 2024 Financial Results - Quantisnow
Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue? - MSN
Xeris Biopharma expects full-year 2025 revenue above estimates - MSN
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026 - BioSpace
Xeris Biopharma Holdings, Inc. ($XERS) CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] Xeris Biopharma Holdings, Inc. SEC Filing - Stock Titan
Xeris Biopharma (NASDAQ: XERS) details 2026 votes on pay, board, auditor - Stock Titan
Xeris (XERS) Year-Ahead Outlook | Q4 2025: EPS Exceeds ExpectationsDark Pool - Cổng thông tin điện tử Tỉnh Sơn La
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):